Osteoporosis screening and treatment in Manitoba: a population-based study
| dc.contributor.author | Ojo, Olasumbo | |
| dc.contributor.examiningcommittee | Chateau, Dan (Community Health Sciences) | en_US |
| dc.contributor.examiningcommittee | Kuo, I Fan (Pharmacy) | en_US |
| dc.contributor.supervisor | Bugden, Shawn (Pharmacy) Falk, Jamie (Pharmacy) | en_US |
| dc.date.accessioned | 2021-04-12T13:50:53Z | |
| dc.date.available | 2021-04-12T13:50:53Z | |
| dc.date.copyright | 2021-04-09 | |
| dc.date.issued | 2021-03 | en_US |
| dc.date.submitted | 2021-04-01T04:23:14Z | en_US |
| dc.date.submitted | 2021-04-10T01:02:23Z | en_US |
| dc.degree.discipline | Pharmacy | en_US |
| dc.degree.level | Master of Science (M.Sc.) | en_US |
| dc.description.abstract | Introduction: Osteoporosis is a bone disease that results in morbidity, mortality, and high healthcare cost. Glucocorticoid (GC) therapy is the most common cause of secondary osteoporosis. The use of aromatase inhibitors (AI) in postmenopausal women results in increases in bone loss of up to 2.5 times. A fracture may be the only clinical manifestation of osteoporosis, hence screening in terms of bone mineral density (BMD) testing to identify those requiring treatment and initiation of osteoporotic treatment when indicated are important steps in the management of the disease. Objective: Assess rates of receipt of BMD tests, and treatment of osteoporosis, and their trends over time in two separate cohorts of high-dose GC users and female breast cancer patients on AI. Method: Administrative healthcare data was used to conduct a retrospective population-based cohort study of individuals ≥ 40 years of age on GC, and AI between 1997 and 2017. BMD test, and treatment rates, trends over time, and prescribing physician specialties were assessed. Results: Both BMD testing and treatment rates were low (4.4% and 9.1%, respectively) in our cohort of high-dose GC users (n = 49,753). Treatment rates remained stable and below 17.0% throughout the 20-year study period between1997 and 2017, in the cohort of AI users (n= 6,726), while BMD test rates increased dramatically from 9.8% at the beginning of the study to 61.8% by the end of the study. For the GC cohort, treatment rates increased from 3.9% at the beginning of the study, to 15.0% in 2003, decreasing steadily thereafter to 6.8% by the end of the study. The majority of the first prescriptions for high-dose GC (74.2%) and AI (53.7%) were written by general practitioners and oncologists, respectively. Conclusion: Although BMD testing rates increased substantially in AI users over the 20-years study span, and FRAX score analysis showed that individuals most at risk had the highest treatment rates in both high-dose GC and AI users, anti-osteoporosis treatment rates appear suboptimal in both cohorts. Efforts to address the increasing osteoporosis management apparent care-gap for these at-risk populations should be considered. | en_US |
| dc.description.note | May 2021 | en_US |
| dc.identifier.uri | http://hdl.handle.net/1993/35424 | |
| dc.language.iso | eng | en_US |
| dc.rights | open access | en_US |
| dc.subject | Osteoporosis | en_US |
| dc.subject | Glucocorticoids | en_US |
| dc.subject | Aromatase inhibitors | en_US |
| dc.subject | Treatment | en_US |
| dc.subject | BMD | en_US |
| dc.subject | Screening | en_US |
| dc.title | Osteoporosis screening and treatment in Manitoba: a population-based study | en_US |
| dc.type | master thesis | en_US |